 (Gut 1995; 37: 574-575) 
Percutaneous liver biopsy as a day case procedure was first described in the United States in 1978 but despite large studies suggesting its safety' it would seem to be underutilised in the United Kingdom. A recent national audit of liver biopsies showed that less than 5% were performed as day case procedures.2 We have routinely undertaken outpatient liver biopsies since 1989 and thought it timely to audit this clinical practice to assess safety, efficacy, and patient acceptability.
All patients had a liver ultrasound before biopsy. After biopsy in the day case unit the patient was asked to lie on their right side and pulse and blood pressure were monitored every 15 minutes for seven hours by nursing staff. The patient was assessed for analgesic requirements throughout this time, examined by the house physician before discharge, and given a post-biopsy advice and side effects leaflet.
Over eight months a questionnaire was given to consecutive patients having a day case biopsy to assess whether they preferred to have their biopsy as an inpatient or as a day case procedure. Patients completed the questionnaire anonymously after their biopsy.
All other liver biopsies performed in the hospital during the 42 month period were defined as inpatient biopsies. Our protocol includes close nursing observations for seven hours post-biopsy, which we feel is an optimal time to detect possible complications although other studies have advocated observation periods as short as three to six hours. ' 5 6 Increasing the use of day case procedures is an important aspect of improving the cost-effectiveness of health care. Our experience confirms that day case liver biopsy is a feasible option and that most patients prefer the convenience of having liver biopsy as a day case procedure. The disparity between the current low national rate, less than 5%/o, and our own practice, greater than 30%, suggests that there is considerable scope for increasing the use of day case liver biopsy in the United Kingdom, with the potential for large cost savings.
In summary day case liver biopsy is safe, effective, and acceptable to patients. It is presently underutilised in the United Kingdom and we advocate its increased use in selected patients who require percutaneous liver biopsy.
